Zealand Pharma A/S
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Emmanuel Dulac PharmD, MBA
- Full Time Employees
- 237
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Sydmarken 11 Copenhagen Denmark 2860
- IPO Date
- Aug 9, 2017
- CIK
- 0001674988
- Website
- zealandpharma.com
- Similar Companies
- Business
- Zealand Pharma A/S, a biotechnology company focused on the discovery, design, development, and commercialization of innovative peptide-based medicines addressing unmet medical needs, operates primarily in the areas of obesity, rare diseases, and chronic inflammation. Founded in 1998 and headquartered in Søborg, Denmark, with additional operations in the United States, the company offers a pipeline of investigational candidates including petrelintide, a long-acting amylin analog for weight management; dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist targeting obesity and low-grade inflammation; survodutide, a long-acting glucagon/GLP-1 receptor dual agonist licensed to Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatohepatitis; ZP6590, a GIP receptor agonist for obesity; dasiglucagon for continuous infusion in congenital hyperinsulinism and other formulations such as Zegalogue for severe hypoglycemia; glepaglutide, a long-acting GLP-2 analog for short bowel syndrome; ZP9830, a Kv1.3 ion channel blocker for T-cell-driven autoimmune diseases; and ZP10068, a complement C3 inhibitor for complement-mediated diseases. Zealand Pharma targets patients with metabolic, gastrointestinal, and inflammatory conditions globally through research, clinical development, and strategic partnerships. In recent developments, the company entered an exclusive collaboration and licensing agreement with Roche in March 2025 to co-develop and co-commercialize petrelintide as a monotherapy and in fixed-dose combination with Roche's CT-388 for obesity, providing upfront payments of USD 1.65 billion and potential total consideration up to USD 5.3 billion; closed this agreement in May 2025 with Phase 2b ZUPREME trials advancing; submitted a Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome; reported positive topline results from a 28-week Phase 1b trial of dapiglutide; completed an upsized equity offering raising approximately DKK 835 million in June 2024 to fund obesity programs; and appointed Steven Johnson as Chief Development Officer to strengthen leadership in obesity innovation.
Company News
Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity
Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)
Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes
Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)
Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons